Surgical Science Sweden AB Stock
Stocks
SUS
SE0014428512
Advanced Medical Equipment & Technology
OTC Markets Traded|
Real-time Estimate
Cboe Europe
11:47:55 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 57.25 SEK | +0.09% |
|
+4.37% | +76.46% |
| 10-21 | Danske Bank raises its price target for Surgical Science to SEK 70 (60), reiterates buy - BN | FW |
| 10-16 | Pareto raises target price for Surgical Science, sees margin target within reach | FW |
| Market Cap | 2.92B 294M 263M 243M 220M 411M 27.91B 418M 1.16B 14.62B 1.1B 1.08B 46.1B | P/E 2026 * |
27.2x | P/E 2027 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise Value | 2.28B 230M 205M 190M 172M 322M 21.83B 327M 904M 11.44B 863M 845M 36.06B | EV / Sales 2026 * |
2.23x | EV / Sales 2027 * | 1.89x |
| Free-Float |
70.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| SUS | Delayed | |
Tradegate
| 4P41 | Real-time | |
|
CBOE
| Real-time | ||
|
Börse Stuttgart
| 4P41 | Delayed | |
|
OTC Markets
| SUSRF | Delayed | |
|
Boerse Muenchen
| 4P41 | Real-time | |
|
Deutsche Boerse AG
| 4P41 | Delayed | |
|
CBOE
| 0AAU | Real-time | |
|
Xetra
| 4P41 | Delayed |
Last Transcript: Surgical Science Sweden AB
| 1 day | +0.26% | ||
| 1 week | +4.37% | ||
| Current month | +11.90% | ||
| 1 month | +11.58% | ||
| 3 months | +75.81% | ||
| 6 months | +71.71% | ||
| Current year | +76.46% |
| 1 week | 54.05 |  | 59.4 |
| 1 month | 48.8 | | 59.4 |
| Current year | 23.7 | | 59.4 |
| 1 year | 23.7 | | 89.05 |
| 3 years | 23.7 | | 196.9 |
| 5 years | 23.7 | | 333.5 |
| 10 years | 8.86 | | 333.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Anders Larsson
CTO | Chief Tech/Sci/R&D Officer | 53 | 1997-07-23 |
Tom Englund
CEO | Chief Executive Officer | 50 | 2024-09-30 |
| Director of Finance/CFO | 56 | 2017-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Bengtsson
BRD | Director/Board Member | 82 | 2004-12-31 |
Roland Bengtsson
CHM | Chairman | 71 | 2010-12-31 |
| Director/Board Member | 59 | 2016-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/22/26 | Free | Chief Executive Officer | 50,000 | 0.0980% | ||
| 12/12/25 | Buy | Chief Financial Officer | 3,000 | 0.0059% | ||
| 12/1/25 | Buy | Chief Executive Officer | 20,000 | 0.0392% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.09% | +4.37% | -35.09% | -53.60% | 294M | |
| +0.57% | +0.10% | +20.62% | +54.50% | 249B | |
| +0.56% | +3.64% | +5.24% | +20.10% | 162B | |
| +0.18% | +4.84% | -17.61% | +75.01% | 157B | |
| -0.61% | +1.13% | -55.52% | -8.48% | 66.22B | |
| -1.09% | +1.39% | +8.63% | +68.94% | 52.3B | |
| +0.70% | +2.78% | -14.77% | -8.54% | 52.18B | |
| +0.89% | +3.19% | +11.36% | +43.36% | 51.34B | |
| +1.44% | +3.55% | +20.02% | +68.66% | 48.79B | |
| +0.60% | +5.69% | +30.48% | +87.76% | 44.57B | |
| Average | +0.36% | +2.49% | -2.66% | +34.77% | 88.38B | |
| Weighted average by Cap. | +0.39% | +1.41% | +2.42% | +46.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.02B 103M 92.15M 85.13M 77.14M 144M 9.8B 147M 406M 5.13B 387M 379M 16.18B | 1.14B 115M 103M 94.83M 85.94M 161M 10.91B 163M 452M 5.72B 431M 422M 18.02B |
| Net income | 107M 10.8M 9.64M 8.91M 8.07M 15.11M 1.03B 15.36M 42.45M 537M 40.53M 39.67M 1.69B | 150M 15.07M 13.46M 12.43M 11.27M 21.08M 1.43B 21.43M 59.24M 750M 56.56M 55.36M 2.36B |
| Net Debt | -636M -64.05M -57.2M -52.84M -47.89M -89.59M -6.08B -91.07M -252M -3.19B -240M -235M -10.04B | -763M -76.88M -68.65M -63.42M -57.47M -108M -7.3B -109M -302M -3.82B -289M -282M -12.05B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-26 | SEK 57.35 | +0.26% | 126,215 |
| 26-10-23 | SEK 57.20 | -0.44% | 61,920 |
| 26-10-22 | SEK 57.45 | -0.17% | 176,869 |
| 26-10-21 | SEK 57.55 | +4.26% | 165,212 |
| 26-10-20 | SEK 55.20 | +0.45% | 92,745 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUS Stock
Select your edition
All financial news and data tailored to specific country editions
